Short answer
CG Oncology, Inc. (CGON) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $2M (down 3.7% year over year) with net income of −$57M.
Q3 2026 key financials · XBRL
- Revenue
- $2M
- −3.7% YoY · +38.6% QoQ
- Net income
- −$57M
- −29.9% YoY · +28.0% QoQ
- Operating margin
- -3943.2%
- EPS (diluted)
- −$0.64
- −12.3% YoY · +28.9% QoQ
Source: XBRL data from the CG Oncology, Inc. (CGON) Q3 2026 10-Q on SEC EDGAR. USD.
CG Oncology, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $1.604M, down $0.062M YoY from $1.666M
- Net loss $56.891M vs $43.808M YoY, operating loss $63.249M vs $51.129M
- Commercial and development revenue $1.604M vs $1.508M, strongest line; license revenue $0 vs $0.158M
- Operating cash use $151.064M through nine months, cash and securities $984.5M
- BLA submission expected in fourth quarter 2026, funding projected for at least twelve months
Risk Factors
- No material changes to previously disclosed risk factors in the 2025 Annual Report
- Regulatory risk: Continued SEC compliance exposure under previously disclosed risks
- Clinical development risk: Product candidates may fail trials or regulatory approval
- Liquidity risk: Future capital needs may require additional financing
- Commercial risk: Competition could limit product adoption and market opportunity
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CG Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.